Orthopedics

Business

CONMED Charts New Course: Surgical Focus After Mixed Q4, But Valuation Questions Linger

CONMED's latest earnings reveal a strategic pivot towards higher-growth surgical platforms, moving away from slower gastroenterology lines. While sales climbed, profitability softened, setting the stage for a crucial transition year as the market weighs the company's reset valuation against its ambitious 2026 roadmap.

Business

Stryker's Record $25.1B Revenue Fuels Valuation Debate: Is the MedTech Giant Still Undervalued?

Stryker Corporation's latest earnings report, driven by its MedSurg, Neurotechnology divisions and the Mako surgical robot, has reignited investor debate. With shares near $370 and a bullish fair value estimate of $427, analysts are weighing robust growth against a premium valuation.

Business

Stryker Caps Record Year with Strong Q4, Bullish on 2026 Despite Market Headwinds

The medical technology giant reports double-digit organic sales growth for the fourth consecutive year, driven by its Mako robotic system and strategic leadership shifts, while navigating tariffs and a shifting competitive landscape.